» Articles » PMID: 33817774

Metabolic Phenotyping of Opioid and Psychostimulant Addiction: A Novel Approach for Biomarker Discovery and Biochemical Understanding of the Disorder

Overview
Journal Br J Pharmacol
Publisher Wiley
Specialty Pharmacology
Date 2021 Apr 5
PMID 33817774
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Despite the progress in characterising the pharmacological profile of drugs of abuse, their precise biochemical impact remains unclear. The metabolome reflects the multifaceted biochemical processes occurring within a biological system. This includes those encoded in the genome but also those arising from environmental/exogenous exposures and interactions between the two. Using metabolomics, the biochemical derangements associated with substance abuse can be determined as the individual transitions from recreational drug to chronic use (dependence). By understanding the biomolecular perturbations along this time course and how they vary across individuals, metabolomics can elucidate biochemical mechanisms of the addiction cycle (dependence/withdrawal/relapse) and predict prognosis (recovery/relapse). In this review, we summarise human and animal metabolomic studies in the field of opioid and psychostimulant addiction. We highlight the importance of metabolomics as a powerful approach for biomarker discovery and its potential to guide personalised pharmacotherapeutic strategies for addiction targeted towards the individual's metabolome. LINKED ARTICLES: This article is part of a themed issue on Building Bridges in Neuropharmacology. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v179.8/issuetoc.

Citing Articles

Identification of Plasma Metabolites Responding to Oxycodone Exposure in Rats.

Vu T, Godbole S, Carrette L, Maturin L, George O, Saba L Metabolites. 2025; 15(2).

PMID: 39997720 PMC: 11857688. DOI: 10.3390/metabo15020095.


Serum cytokines and inflammatory proteins in individuals with heroin use disorder: potential mechanistically based biomarkers for diagnosis.

Butelman E, Huang Y, Cathomas F, Gaudreault P, Roussos P, Russo S Transl Psychiatry. 2024; 14(1):414.

PMID: 39362849 PMC: 11450096. DOI: 10.1038/s41398-024-03119-z.


Exploring the progression of drug dependence in a methamphetamine self-administration rat model through targeted and non-targeted metabolomics analyses.

Song S, Kim S, Jang W, Ryu I, Jeong C, Lee S Sci Rep. 2024; 14(1):22543.

PMID: 39343795 PMC: 11439939. DOI: 10.1038/s41598-024-73247-5.


Neuroinflammation and Neurometabolomic Profiling in Fentanyl Overdose Mouse Model Treated with Novel β-Lactam, MC-100093, and Ceftriaxone.

Alasmari M, Alasmari F, AlSharari S, Alasmari A, Ali N, Ahamad S Toxics. 2024; 12(8).

PMID: 39195706 PMC: 11360732. DOI: 10.3390/toxics12080604.


Tackling new psychoactive substances through metabolomics: UHPLC-HRMS study on natural and synthetic opioids in male and female murine models.

Di Francesco G, Montesano C, Vincenti F, Bilel S, Corli G, Petrella G Sci Rep. 2024; 14(1):9432.

PMID: 38658766 PMC: 11043364. DOI: 10.1038/s41598-024-60045-2.